Search results for "HUMAN HEALTH"

showing 10 items of 1622 documents

Can aminothiols be distinguished from reactive oxygen species?

2016

Glutathione is considered the major natural antioxidant, protecting cells from oxidative stress. Patel and colleagues used plasma levels of the aminothiols cystine and glutathione to quantify oxidative stress in patients with coronary artery disease, and show that the cystine/glutathione ratio is associated with increased mortality. Is this a new approach for clinical risk stratification?

0301 basic medicinemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentCystine030204 cardiovascular system & hematologymedicine.disease_causeCoronary artery disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineIn patientComputingMilieux_MISCELLANEOUSchemistry.chemical_classificationReactive oxygen speciesbusiness.industryPlasma levelsGlutathionemedicine.disease3. Good health030104 developmental biologyEndocrinologychemistryCardiologyCardiology and Cardiovascular MedicinebusinessOxidative stress
researchProduct

Short Term Palmitate Supply Impairs Intestinal Insulin Signaling via Ceramide Production

2016

International audience; The worldwide prevalence of metabolic diseases is increasing, and there are global recommendations to limit consumption of certain nutrients, especially saturated lipids. Insulin resistance, a common trait occurring in obesity and type 2 diabetes, is associated with intestinal lipoprotein overproduction. However, the mechanisms by which the intestine develops insulin resistance in response to lipid overload remain unknown. Here, we show that insulin inhibits triglyceride secretion and intestinal microsomal triglyceride transfer protein expression in vivo in healthy mice force-fed monounsaturated fatty acid-rich olive oil but not in mice force-fed saturated fatty acid…

0301 basic medicinemedicine.medical_specialtyCeramidemedicine.medical_treatmentPalmitic Acid[SDV.BC]Life Sciences [q-bio]/Cellular BiologyPalm OilCeramidesBiochemistryPalmitic acidMice03 medical and health scienceschemistry.chemical_compoundInsulin resistance[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyInternal medicinemedicineAnimalsHumansInsulinPlant OilsIntestinal MucosaPhosphorylationMolecular BiologyComputingMilieux_MISCELLANEOUS2. Zero hungerbiologyTriglycerideInsulinCell BiologyLipid signalingmedicine.diseaseLipids3. Good healthInsulin receptorEnterocytes030104 developmental biologyEndocrinologychemistrySaturated fatty acidbiology.proteinCaco-2 CellsProto-Oncogene Proteins c-akt[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologySignal TransductionJournal of Biological Chemistry
researchProduct

Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting

2019

We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health c…

0301 basic medicinemedicine.medical_specialtyCognitiveGenital Neoplasms FemaleInternational Cooperation[SDV.CAN]Life Sciences [q-bio]/CancerCancer Chemotherapy Cognitive Gynecologic Offspring Pregnancy[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics03 medical and health sciencesGenital Neoplasms Female/therapyGynecologicOffspring0302 clinical medicineSDG 3 - Good Health and Well-beingPregnancyHealth caremedicinePrenatal Exposure Delayed Effects/etiologyHumansChemotherapyRadiation treatment planningIntensive care medicineSocieties MedicalCancerPregnancy Complications Neoplastic/therapyPregnancyVaginal deliverybusiness.industryCancerHematologymedicine.diseasePrognosis3. Good healthCancer registryLong-term care030104 developmental biologyOncology030220 oncology & carcinogenesisPrenatal Exposure Delayed EffectsPractice Guidelines as TopicFemalePractice Guidelines as Topic/standardsbusinessBreast feedingPregnancy Complications Neoplastic
researchProduct

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease

2018

Gaucher Disease type 1 (GD1) is a lysosomal disorder that affects many systems. Therapy improves the principal manifestations of the condition and, as a consequence, many patients show a modified phenotype which reflects manifestations of their disease that are refractory to treatment. More generally, it is increasingly recognised that information as to how a patient feels and functions [obtained by patient- reported outcome measurements (PROMs)] is critical to any comprehensive evaluation of treatment. A new set of management goals for GD1 in which both trends are reflected is needed. To this end, a modified Delphi procedure among 25 experts was performed. Based on a literature review and …

0301 basic medicinemedicine.medical_specialtyConsensusDelphi study; Gaucher disease; Management goals; PROMs; TherapyDelphi methodEarly detectionGaucher diseaseDiseasePROMs03 medical and health sciences0302 clinical medicineQuality of life (healthcare)HumansMedicineIntensive care medicineSet (psychology)Molecular BiologyComputingMilieux_MISCELLANEOUSManagement goalsbusiness.industryDisease ManagementType 1 Gaucher DiseaseExpert consensus[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyCell BiologyHematologySocial engagementDelphi study3. Good healthEurope030104 developmental biology030220 oncology & carcinogenesisQuality of LifePhysical therapyMolecular MedicineTherapybusinessBlood Cells, Molecules, and Diseases
researchProduct

High prevalence of arrhythmic and myocardial complications in patients with cardiac glycogenosis due to PRKAG2 mutations

2016

International audience; AIMS: Mutations in PRKAG2, the gene encoding for the γ2 subunit of 5'-AMP-activated protein kinase (AMPK), are responsible for an autosomal dominant glycogenosis with a cardiac presentation, associating hypertrophic cardiomyopathy (HCM), ventricular pre-excitation (VPE), and progressive heart block. The aim of this study was to perform a retrospective time-to-event study of the clinical manifestations associated with PRKAG2 mutations.METHODS AND RESULTS: A cohort of 34 patients from 9 families was recruited between 2001 and 2010. DNA were sequenced on all exons and flanking sequences of the PRKAG2 gene using Sanger sequencing. Overall, four families carried the recur…

0301 basic medicinemedicine.medical_specialtyHeart blockCardiomyopathymedicine.medical_treatmentCardiomyopathyDisease030204 cardiovascular system & hematologySudden cardiac deathTime-to-event study03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPhysiology (medical)Internal medicineWolff–Parkinson–WhiteVentricular pre-excitationmedicineHeart transplantationbusiness.industryIncidence (epidemiology)Hypertrophic cardiomyopathy[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseasePRKAG23. Good health030104 developmental biologyCohortCardiologyCardiology and Cardiovascular Medicinebusiness
researchProduct

In response to the article published by Fukaya et al., entitled: “Relationships between the center of pressure and the movements of the ankle and kne…

2017

International audience

0301 basic medicinemedicine.medical_specialtyKnee JointMovementOsteoarthritisKnee Jointbiomechanicsknee osteoarthritisBiomechanical Phenomena[ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationCenter of pressure (terrestrial locomotion)center of pressuremedicineHumansOrthopedics and Sports MedicineIn patientGaitComputingMilieux_MISCELLANEOUS030203 arthritis & rheumatologybusiness.industryBiomechanicsknee braceOsteoarthritis Kneemedicine.diseaseBiomechanical Phenomenalocomotion030104 developmental biologymedicine.anatomical_structureAnkleAnklebusinessAnkle JointMedial knee
researchProduct

Evaluation of an Antioxidant and Anti-inflammatory Cocktail Against Human Hypoactivity-Induced Skeletal Muscle Deconditioning

2020

International audience; Understanding the molecular pathways involved in the loss of skeletal muscle mass and function induced by muscle disuse is a crucial issue in the context of spaceflight as well as in the clinical field, and development of efficient countermeasures is needed. Recent studies have reported the importance of redox balance dysregulation as a major mechanism leading to muscle wasting. Our study aimed to evaluate the effects of an antioxidant/anti-inflammatory cocktail (741 mg of polyphenols, 138 mg of vitamin E, 80 mu g of selenium, and 2.1 g of omega-3) in the prevention of muscle deconditioning induced by long-term inactivity. The study consisted of 60 days of hypoactivi…

0301 basic medicinemedicine.medical_specialtyPhysiologymedicine.medical_treatment[SDV]Life Sciences [q-bio]Context (language use)Sciences du Vivant [q-bio]/Médecine humaine et pathologieBed restmedicine.disease_causelcsh:Physiology03 medical and health sciencesSciences du Vivant [q-bio]/Autre [q-bio.OT]0302 clinical medicineAtrophyDeconditioningInternal medicinePhysiology (medical)medicineoxidative stresscell signalingWastingOriginal Research[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologylcsh:QP1-981business.industrySkeletal musclemuscle wastingmedicine.disease3. Good health[SDV] Life Sciences [q-bio]030104 developmental biologyEndocrinologymedicine.anatomical_structureantioxidantsinactivityFisiologia humanamedicine.symptombusinessHypoactivity030217 neurology & neurosurgeryOxidative stress[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Hypoxie et régénération cardiaque : une nouvelle approche paradoxale de la cardioprotection

2017

IF 2.331; International audience

0301 basic medicinemedicine.medical_specialtyReactive oxygen species metabolismTranscription GeneticCardiac pathologyEnergy metabolismCardiac metabolismCardioprotectionHypoxie03 medical and health sciencesInternal medicinemedicineRégénérationAnimalsHumansRegenerationMyocytes CardiacTissue survivalHypoxiaCoeurCell ProliferationCardioprotectionHeart FailureTissue Survivalbusiness.industryOxygen metabolismHeartGeneral MedicineRecovery of FunctionHypoxia (medical)[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemCell HypoxiaOxygenOxidative Stress030104 developmental biologyGene Expression RegulationAnesthesiaCardiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessEnergy MetabolismReactive Oxygen SpeciesSignal TransductionArchives of cardiovascular diseases
researchProduct

Staphylococcus aureus bloodstream infection in patients with prosthetic joint included in the prospective VIRSTA cohort study: frequency and time of …

2019

International audience; Among 143 patients of the VIRSTA cohort study with Staphylococcus aureus bacteremia and an arthroplasty implanted for more than a year, S. aureus periprosthetic joint infection was observed in 19%. Signs of infection (pain and swelling) were always present, in median 1 day (range, 0-21 days) after onset of bacteremia. Staphylococcus aureus has both a high potential for metastatic infection and a high affinity for foreign material. Possible prosthesis infection is of clinical concern in all patients with preexisting prosthetic materials experiencing S. aureus bloodstream infection (SAB). Prosthetic joints are especially prone to infection during the course of bacterem…

0301 basic medicinemedicine.medical_specialtyStaphylococcus aureusmedicine.medical_treatment030106 microbiologyPeriprostheticbloodstream infectionmedicine.disease_causeProsthesis03 medical and health sciences0302 clinical medicineInternal medicinemedicine030212 general & internal medicineprosthetic joint infectionProspective cohort studybusiness.industryBrief Reportmedicine.diseaseArthroplasty3. Good healthInfectious DiseasesOncologyStaphylococcus aureusBacteremiaImplantbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCohort study
researchProduct

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct